[Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].
BACKGROUND
Interventions against osteoporosis may reduce the incidence of fractures in patients and costs to society, but they also incur additional expenditure and thus call for economic evaluation. The aim of this paper was to evaluate existing literature by applying cost-effectiveness (CEA) and cost-utility analyses (CUA) to pharmacological treatment of osteoporosis.


METHODS
MEDLINE and the reference lists of relevant papers were searched to identify original papers on the subject. Studies were included if they were peer reviewed, written in English or a Scandinavian language, and reported CEA or CUA for a specified pharmacological intervention.


RESULTS
Of the 37 identified studies, 16 met the inclusion criteria (ten CUA and six CEA), and 21 studies were excluded. Of the studies examined, 13 studies concerned hormone replacement therapy (HRT), four bisphosphonate, four calcitonin, and four calcium supplementation and/or vitamin D treatment. All were based on simulations of the long-term effects of the intervention with respect to cost and effect. However, the studies varied widely in patient selection and assumptions about duration and effectiveness of intervention, assessment of quality of life, and mortality following hip fracture.


CONCLUSIONS
The published studies rely on limited empirical data as regards the effect of treatment, costs, and adverse effects. Several, however, indicate that some interventions may be cost-effective in high-risk groups.
Christensen
Palle Mark
PM
Odense Universitetshospital, endokrinologisk afdeling, Syddansk Universitet, Klinisk Farmakologi og Sundhedsøkonomi, DSI Institut for Sundhedsvaesen, København. kim.brixen@dadlnet.dk
Brøsen
Kim
K
Brixen
Kim T
KT
Beck-Nielsen
Henning
H
Søgaard
Jes
J
Kristiansen
Ivar Sønbø
IS
D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage; D002118:Calcium / Q000008:administration & dosage; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D004164:Diphosphonates / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy / Q000191:economics*; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D020249:Hormone Replacement Therapy / Q000191:economics*; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000191:economics*; D011372:Progestins / Q000008:administration & dosage; D014807:Vitamin D / Q000008:administration & dosage
D004164:Diphosphonates; D011372:Progestins; D014807:Vitamin D; D002116:Calcitonin; D002118:Calcium